CITADEL ADVISORS LLC

Position in PVLA — Palvella Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Back to PVLA Full portfolio

Position in PVLA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$2,551,834

+$2,275,924 QoQ

Shares Held

20,472

+676.6% QoQ

Ownership

0.143%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2024

3 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in PVLA Over Time

Shares Held

Position Value (USD)

Derivatives in PVLA

reported options exposure · as of Mar 31, 2026

CallValue

$3,515,130

CallShares

28,200

PutValue

$972,270

PutShares

7,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. PVLA ranks #179 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INSM	INSMED Inc	2,182,571	$356,894,009
2	ONC	BeOne Medicines Ltd.	1,032,298	$306,561,536
3	BMRN	Biomarin Pharmaceutical Inc	4,512,634	$254,918,694
4	JAZZ	Jazz Pharmaceuticals plc	1,259,444	$238,097,887
5	MDGL	Madrigal Pharmaceuticals, Inc.	453,843	$237,573,195
6	BBIO	BridgeBio Pharma, Inc.	3,173,940	$235,696,783
7	TERN	Terns Pharmaceuticals, Inc.	3,218,810	$169,695,662
8	PTGX	Protagonist Therapeutics, Inc	1,551,900	$163,570,260

All Filings in PVLA

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$972,270	7,800	-61.9%	Put	Defined	2026-05-15
2026-03-31	$2,551,834	20,472	-27.4%	Shares	Defined	2026-05-15
2026-03-31	$3,515,130	28,200	+969.8%	Call	Defined	2026-05-15
2025-12-31	$275,910	2,636	-74.7%	Shares	Defined	2026-02-17
2024-12-31	$124,896	10,408	—	Shares	Defined	2025-02-14
No filing history on record for this holder in this stock.